206 related articles for article (PubMed ID: 31036835)
41. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
42. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
43. ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy.
Liu C; Zhang Y; Jian X; Tan X; Lu M; Ouyang J; Liu Z; Li Y; Xu L; Chen L; Lin Y; Xie L
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627168
[TBL] [Abstract][Full Text] [Related]
44. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD; Snyder A
Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
[TBL] [Abstract][Full Text] [Related]
45. Cancer Neoantigens.
Schumacher TN; Scheper W; Kvistborg P
Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
[TBL] [Abstract][Full Text] [Related]
46. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
47. Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?
Manoutcharian K; Guzman Valle J; Gevorkian G
Arch Immunol Ther Exp (Warsz); 2021 Apr; 69(1):12. PubMed ID: 33909124
[TBL] [Abstract][Full Text] [Related]
48. Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening.
Zhang J; Shen L; Johnston SA
Sci Rep; 2018 Nov; 8(1):17366. PubMed ID: 30478295
[TBL] [Abstract][Full Text] [Related]
49. Neoantigens encoded in the cancer genome.
Schumacher TN; Hacohen N
Curr Opin Immunol; 2016 Aug; 41():98-103. PubMed ID: 27518850
[TBL] [Abstract][Full Text] [Related]
50. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
Ingels J; De Cock L; Mayer RL; Devreker P; Weening K; Heyns K; Lootens N; De Smet S; Brusseel M; De Munter S; Pille M; Billiet L; Goetgeluk G; Bonte S; Jansen H; Lint SV; Leclercq G; Taghon T; Menten B; Vermaelen K; Impens F; Vandekerckhove B
Cytotherapy; 2022 Feb; 24(2):213-222. PubMed ID: 34696961
[TBL] [Abstract][Full Text] [Related]
51. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
52. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
[TBL] [Abstract][Full Text] [Related]
53. Applications of Immunogenomics to Cancer.
Liu XS; Mardis ER
Cell; 2017 Feb; 168(4):600-612. PubMed ID: 28187283
[TBL] [Abstract][Full Text] [Related]
54.
Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
[TBL] [Abstract][Full Text] [Related]
55. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
[TBL] [Abstract][Full Text] [Related]
56. Peptide vaccines in early breast cancer.
Criscitiello C; Viale G; Curigliano G
Breast; 2019 Apr; 44():128-134. PubMed ID: 30769238
[TBL] [Abstract][Full Text] [Related]
57. Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses.
Shukla GS; Sun YJ; Pero SC; Sholler GS; Krag DN
J Immunol Methods; 2018 Sep; 460():51-62. PubMed ID: 29906453
[TBL] [Abstract][Full Text] [Related]
58. Lack of shared neoantigens in prevalent mutations in cancer.
Ragone C; Cavalluzzo B; Mauriello A; Tagliamonte M; Buonaguro L
J Transl Med; 2024 Apr; 22(1):344. PubMed ID: 38600547
[TBL] [Abstract][Full Text] [Related]
59. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
60. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
